Friday 6 November 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.

Revenue: −0.24%
EPS: +2.48%
Free cash flow: +17.4%
Total debt: +37.5%

Quarter to June 2026, against a year earlier

81.72 7.48 −8.39%

Follow ZTS

Alert me

Market cap: $33.9B
P/E: 13.4×
Fwd P/E: 14.2×
Dividend yield: 2.59%
F-score: 7/9
Altman Z: 5.73
Beneish M: −2.45
Dividend safety: 88/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Zoetis Inc. (ZTS) revenue by segment, product and region

	Q4 FY2012	Q3 FY2012	Q2 FY2012	Q1 FY2012	Q4 FY2011	Q3 FY2011	Q2 FY2011	Q1 FY2011
Anti-infectives	‡	‡	‡	‡	‡	‡	‡	‡
Vaccines	‡	‡	‡	‡	‡	‡	‡	‡
Other pharmaceutical	‡	‡	‡	‡	‡	‡	‡	‡
Parasiticides	‡	‡	‡	‡	‡	‡	‡	‡
Medicated feed additives	‡	‡	‡	‡	‡	‡	‡	‡
Other Non Pharmaceuticals	‡	‡	‡	‡	‡	‡	‡	‡
Cattle	‡	‡	‡	‡	‡	‡	‡	‡
Dogs and Cats	‡	‡	‡	‡	‡	‡	‡	‡
Swine	‡	‡	‡	‡	‡	‡	‡	‡
Poultry	‡	‡	‡	‡	‡	‡	‡	‡
Horses	‡	‡	‡	‡	‡	‡	‡	‡
Sheep and other	‡	‡	‡	‡	‡	‡	‡	‡
Contract manufacturing & human health	‡	‡	‡	‡	‡	‡	‡	‡
Companion Animal	‡	‡	‡	‡	‡	‡	‡	‡
Livestock	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Zoetis Inc. (ZTS) revenue by segment, product and region

Stockrow Weekly